Summarized by Masters of Longevity from Longevity Technology.
FDA 510(k) cleared NEXT‑Cue to support MCI five‑year prognosis.
Key Takeaways
- NEXT‑Cue is cleared to estimate five‑year Alzheimer’s risk.
- The software is trained on MRI, demographics, and cognitive scores.
- Clinical performance data were not provided and remain unproven.
